InBios International
Seattle, WA, United StatesFounded 1996Industry
InBios International makes diagnostic tests for high-consequence infectious diseases. CBRNE-relevant work is a notable product line according to its website. It is headquartered in Seattle, WA, United States.
What it does
Threats covered
Categories
Profile
InBios International is a Seattle biotechnology company, privately owned and founded in 1996, not 2008, that develops and manufactures rapid and ELISA diagnostic tests for infectious diseases and biothreats. It partnered with the Biomedical Advanced Research and Development Authority in 2017 on the Active Anthrax Detect Plus rapid test, which was later cleared by the US Food and Drug Administration through the De Novo pathway, an approval that BARDA counted as its 69th.
More profile
It also received BARDA and National Institutes of Health supported work on Ebola diagnostics. Contract values and total funding were not read.
Ownership
Privately owned; owner-managed
Sources (5)
Not verified or not found
- Contract values: not read.
- Date of the De Novo clearance: the BARDA page is dated 2023; exact date not confirmed.
- Ownership beyond private: not read.
Questions
What does InBios International do?
InBios International makes diagnostic tests for high-consequence infectious diseases. CBRNE-relevant work is a notable product line according to its website.
Where is InBios International based?
HQ (as found): Seattle, WA. HQ country: US.
Who owns InBios International?
Privately owned; owner-managed
Profiles are compiled from public sources and sampled-checked, not fully audited. Last verified 17 October 2026. Report a correction